Breaking news and analysis from time.com. Politics, world news, photos, video, tech reviews, health, science, and ...
A new drug targets RAS cancer-causing cells in the pancreas, nearly doubling survival rates in clinical trials. Here's how ...
A new daily pill called daraxonrasib is showing promise against advanced pancreatic cancer in a first-in-human trial of 168 patients with RAS mutations.
In a family of killer diseases, pancreatic cancer has long been one of the scariest. It could grow undetected for years, and ...
Daraxonrasib doubles survival — a RAS‑targeting drug development breakthrough.
Short-Term Surgical Mission in Sub-Saharan Country, Experience of a Breast-Dedicated Team: Reviewing the Past and Stepping Toward the Last Mission Rapidly expanding systemic treatment options, ...
Enhancing Readability of Lay Abstracts and Summaries for Urologic Oncology Literature Using Generative Artificial Intelligence: BRIDGE-AI 6 Randomized Controlled Trial We trained and tested ML systems ...
MultiValent Biotherapies, Inc. (MultiValent), a private biotechnology company developing targeted drug conjugate therapies for cancer, announced a $27.425 million first closing of its Series A ...
Share on Pinterest Scientists are looking at the effects of the keto diet on cancer therapies. Dulin/Getty Images A ketogenic diet can interact with certain cancer therapies to block the development ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results